Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | PRKCI | P41743 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12078457 | 0.79 | PARP1 (0.58) | PARP1 | |
| SCHEMBL8118010 | 0.76 | GAA (0.39) | PARP1DYRK1APRKCI | |
| SCHEMBL15427984 | 0.76 | CYP3A4 (0.39) | PARP1DYRK1APRKCI | |
| SCHEMBL3643840 | 0.76 | PARP1 (0.46) | PARP1PRKCI | |
| SCHEMBL7484709 | 0.76 | PARP1 (0.39) | PARP1DYRK1APRKCI | |
| SCHEMBL23714719 | 0.76 | PARP1 (0.42) | PARP1 | |
| SCHEMBL30748780 | 0.76 | PARP1 (0.42) | PARP1 | |
| SCHEMBL31520283 | 0.73 | MAPT (0.41) | — | |
| SCHEMBL6637296 | 0.72 | PARP1 (0.59) | PARP1DYRK1APRKCI | |
| SCHEMBL29661355 | 0.72 | PARP1 (0.59) | PARP1DYRK1APRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049746-A1 | COMPOSITIONS COMPRISING WERNER SYNDROME HELICASE INHIBITORS AND METHODS OF USING THE SAME | EIKON THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
| CN-117242060-A | Isoindolinone compounds | 蒙特罗萨医疗公司 | 2023-12-15 | — | — | CN | disclosed |
| EP-4277901-A1 | ISOINDOLINONE COMPOUNDS | Monte Rosa Therapeutics, Inc. (US) | 2023-11-22 | — | — | EP | disclosed |
| WO-2022152821-A1 | ISOINDOLINONE COMPOUNDS | MONTE ROSA THERAPEUTICS AG (CH) | 2022-07-21 | — | — | WO | disclosed |
| EP-2873660-B1 | INDOLECARBOXAMIDE DERIVATIVE | ASTELLAS PHARMA INC (JP) | 2016-10-26 | — | — | EP | disclosed |
| CN-104395312-B | The Spirocyclic derivatives of 4,5-dihydro-pyrazolo [3,4-c] pyridin-2-ones, its preparation method and application | SICHUAN HAISCO PHARMACEUTICAL CO.,LTD. (CN) | 2016-04-27 | — | — | CN | disclosed |
| EP-2873660-A1 | INDOLECARBOXAMIDE DERIVATIVE | Astellas Pharma Inc. (JP) | 2015-05-20 | — | — | EP | disclosed |
| WO-2014202027-A1 | SPIROCYCLIC DERIVATIVE OF 4,5-DIHYDROPYRAZOLO[3,4-C]PYRIDINE-2-ONE, PREPARATION METHOD AND USE THEREOF | 四川海思科制药有限公司 (CN) | 2014-12-24 | — | — | WO | disclosed |
| WO-2014169845-A2 | 4,5-DIHYDRO-PYRAZOLO [3, 4-C] PYRID-2-ONES, PREPARATION METHOD AND APPLICATION THEREOF | 四川海思科制药有限公司 (CN) | 2014-10-23 | — | — | WO | disclosed |
| US-8227501-B2 | 1,6-dihydro-2H-3-oxa-6-aza-as-indacene compounds | FERRER INTERNACIONAL, S.A. (ES) | 2012-07-24 | — | — | US | disclosed |
| US-8227501-B2 | 1,6-dihydro-2H-3-oxa-6-aza-as-indacene compounds | FERRER INTERNACIONAL, S.A. (ES) | 2012-07-24 | — | — | US | disclosed |
| US-8227501-B2 | 1,6-dihydro-2H-3-oxa-6-aza-as-indacene compounds | FERRER INTERNACIONAL, S.A. (ES) | 2012-07-24 | — | — | US | disclosed |
| EP-2350088-A1 | 1,6-DIHYDRO-2H-3-OXA-6-AZA-AS-INDACENE COMPOUNDS | Ferrer Internacional, S.A. (ES) | 2011-08-03 | — | — | EP | disclosed |
| US-20110144178-A1 | 1 ,6-DIHYDRO-2H-3-OXA-6-AZA-AS-INDACENE COMPOUNDS | FERRER INTERNACIONAL, S.A. (ES) | 2011-06-16 | — | — | US | disclosed |
| US-20110144178-A1 | 1 ,6-DIHYDRO-2H-3-OXA-6-AZA-AS-INDACENE COMPOUNDS | FERRER INTERNACIONAL, S.A. (ES) | 2011-06-16 | — | — | US | disclosed |
| US-20110144178-A1 | 1 ,6-DIHYDRO-2H-3-OXA-6-AZA-AS-INDACENE COMPOUNDS | FERRER INTERNACIONAL, S.A. (ES) | 2011-06-16 | — | — | US | disclosed |
| WO-2010012789-A1 | 1,6-DIHYDRO-2H-3-OXA-6-AZA-AS-INDACENE COMPOUNDS | FERRER INTERNACIONAL S. A. (ES) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010012789-A1 | 1,6-DIHYDRO-2H-3-OXA-6-AZA-AS-INDACENE COMPOUNDS | FERRER INTERNACIONAL S. A. (ES) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144178-A1 | 1 ,6-DIHYDRO-2H-3-OXA-6-AZA-AS-INDACENE COMPOUNDS | MTNR1A, MTNR1B, ADORA2A | PARP1 1889/4885DYRK1A 996/4885PRKCI 4542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.